The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Filing marks first protein-based vaccine submitted to MHRA for authorization
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Cobas pure provides clinical labs with access to more than 230 diagnostic tests across a wide range of disease areas including infectious diseases, oncology and cardiology
It is a recombinant nanoparticle protein-based vaccine
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Subscribe To Our Newsletter & Stay Updated
